Presentations

2022 - SITC: SQ2270, a Novel MMAE-based Click Chemistry Therapeutic, Promotes Tumor Growth Inhibition and Extensive Immune Cell Infiltration in the RENCA Cancer Model

2022 - SITC: Treatment with SQ3370, a doxorubicin-based click chemistry therapeutic, promotes immune activation in the tumor microenvironment

2022 - AACR Special Conference: Tumor Immunology and Immunotherapy - Combining SQ3370, a Doxorubicin-based Therapeutic, with TLR and STING Agonists Enhances Antitumor Effect in Murine Tumor Models

2022 - ESMO: Phase 1 Clinical & Immunologic Data of SQ3370 in Advanced Solid Tumors

2022 - World ADC: Click Activated Protodrugs Against Cancer (CAPAC™) A modular platform for tumor-directed oncology therapeutics

2022 - ACS: CAPAC™ A modular platform for tumor-directed oncology therapeutics

2022 - ASCO: Interim Phase 1 results for SQ3370 in advanced solid tumors

2022 - AACR: SQ3370 in Advanced Solid Tumors - Interim Phase 1 Results

2022 - AACR: Click Activated Protodrugs Against Cancer (CAPAC™) A modular platform for tumor-directed oncology therapeutics

2021 - SITC: Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform

2021 - SITC: Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity

2021 - CTOS: First-in-human trial of SQ3370 in relapsed or refractory soft tissue sarcoma and other solid tumors, proof-of-concept for the click chemistry- based CAPAC platform

2021 - CTOS: Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances Antitumor Efficacy, Safety and Pharmacokinetics of Cancer Therapeutics

2021 - ESMO: Early pharmacokinetic data from a Phase I study of SQ3370 (NCT04106492) in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform

2021 - ESMO: Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances the Safety, Pharmacokinetics, and Antitumor Efficacy of Cancer Therapies in vivo

2021 - AACR: First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Advanced Solid Tumors

2021 - AACR: The CAPAC Platform Maximizes Therapeutic Benefit and Reduces Systemic Cytotoxic Exposure in Small and Large Animals

2020 - SITC: First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Advanced Solid Tumors

2020 - SITC: SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses

2020 - MSTS: SQ3370, a Novel Technology to Locally Capture and Activate Cytotoxic Drugs, Produces Systemic Responses in Injected and Non-injected Lesions via Immune Activation.

2020 - CTOS: First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Soft Tissue Sarcomas and Other Advanced Solid Tumors

2020 - CTOS: SQ3370 Activates Cytotoxic Drugs at Tumor via Click Chemistry and Produces Sustained Responses in Injected and Non-injected Lesions in Preclinical Models

2020 - AACR: SQ3370, a Local Activation Therapy (LAT) of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation.

2019 - ASCO: SQ3370: Biomaterial-dependent local drug activation of systemic cytotoxic prodrugs

2019 - AACR: SQ3370 enhances the safety of chemotherapeutics via local activation therapy

2018 - ASCO: Local drug activation: safer cytotoxics for local tumors